Cell Cycle Inhibitors: AURKA/B
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: CDK4/6 Inhibitors
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: CHK1/2 Inhibitors
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: p53 Activators
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: Wee1 Inhibitors
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: AURKA/B
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01091428 | I/II | Alisertib, Paclitaxel | Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer | Alisertib+paclitaxel shows promising increase in PFS compared to paclitaxel alone, with a manageable safety profile Ali+Pac vs Pac: ORR: 48 vs 37% pub 2019 |
Cell Cycle Inhibitors: CDK4/6 Inhibitors
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03531645 | II | Abemaciclib, Fulvestrant | A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | Neoadjuvant treatment with fulvestrant and abemaciclib is tolerable and demonstrates unprecedented response and complete gross resection rates in Low Grade Serous OC ORR: 60% (n=15) 7 patients w/ IDS: |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01536743 | II | Palbociclib | A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | Palbociclib has modest single agent activity in unselected patients, but shows encouraging activity in patients with CDKN2A loss or CDK6 AMP ORR: 6% 6 patients w/ response by CA125 or RECIST: abs Jun 2016 and poster |
| NCT02657928 | II | Letrozole, Ribociclib | A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers. | Ribociclib+letrozole is active in ER+ OC with 25% achieving PFS for 23 weeks or longer, but greatest benefit is seen in LGSOC ORR (HGSOC): 0% abs May 2019 and presentation |
| NCT03673124 | II | Letrozole, Ribociclib | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | The combination of letrozole plus ribociclib demonstrates promising activity in women with recurrent LGSOC ORR: 23% abs Mar 2023 and presentation |
Cell Cycle Inhibitors: CHK1/2 Inhibitors
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03414047 | II | ACR-368 | A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | ACR-368 (prexasertib) demonstrates durable single agent activity in a subset of patients with platinum resistant HGSOC regardless of clinical characteristics or prior therapy ORR: 12.1% pub 2022 |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02203513 | II | ACR-368 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer | Promising activity in heavily pretreated BRCA WT patients, including those with CCNE1 alterations, but modest activity in BRCA MUT patients BRCA WT: BRCA MUT: pub 2018, abs May 2020 and poster |
Cell Cycle Inhibitors: p53 Activators
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT02098343 | II | Carboplatin, Liposomal doxorubicin, Eprenetapopt | PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | Encouraging activity of APR-246+carboplatin+liposomal doxorubicin in TP53-mutated Pt-S and partially Pt-S patients ORR: 62% abs Jun 2016 |
Cell Cycle Inhibitors: Wee1 Inhibitors
Platinum-Sensitive (Pt-S): Treatment given for recurrence occurring 6 months or more after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01357161 | II | Adavosertib, Carboplatin, Paclitaxel | A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer | Improved PFS with addition of AZD1775 Ada+CarboPt+Pac vs CarboPt+Pac: ORR: 81.4 vs 75.8% pub 2020 |
Platinum-Resistant/Refractory (Pt-R/Rf): Treatment given for recurrence occurring less than 6 months after last platinum-based treatment or for progression during last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01164995 | II | Adavosertib, Carboplatin | Phase II Pharmacological Study With Wee-1 Inhibitor MK-1775 Combined With Carboplatin in Patients With p53 Mutated Epithelial Ovarian Cancer and Early Relapse (< 3 Months) or Progression During Standard First Line Treatment | Promising activity of adavosertib+carboplatin combination in TP53-mutated primary platinum resistant and platinum refractory ovarian cancer; a large proportion of responding patient had CCNE1 AMP ORR: 41% pub 2016, pub 2023 |
| NCT02101775 | II | Adavosertib, Gemcitabine | A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | Addition of adavosertib to gemzar improves ORR, PFS and OS Gem+Ada vs Gem: ORR: 25 vs 7% pub 2021 |
| NCT02272790 | II | Adavosertib, Carboplatin | A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adavosertib+carboplatin shows efficacy in primary platinum resistant ovarian cancer with greatest benefit in patients receiving adavosertib weeks 1–3+carboplatin, but with increased hematologic toxicity
Ada week 1+CarboPt: Ada week 1-3+CarboPt pub 2022 |
| NCT04516447 | I | Azenosertib, Carboplatin, Liposomal doxorubicin, Paclitaxel, Gemcitabine | A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer | Azenosertib (ZN-c3), combined with chemotherapy, is well-tolerated and demonstrates clinical activity in patients with Pt-R or Pt-Rf OC Aze+CarboPt: Aze+Pac: Aze+Gem: (n=13) Aze+PLD: abs Jun 2023 and poster |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03579316 | II | Adavosertib, Olaparib | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | Adavosertib alone and in combination with olaparib demonstrates efficacy in patients with PARPi-resistant OC irrespective of BRCA status Ada+Ola vs Ada: ORR: 29 vs 23%; DoR: 6.4 vs 5.5 months: DCR (4 months): 89 vs 63%; PFS: 6.8 vs 5.5 months BRCA MUT: abs Jun 2021 and presentation |
| NCT02482311 | Ib | Adavosertib | A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | Adavosertib is well tolerated and shows preliminary antitumor activity. No clear correlation between genomic profile and clinical response 30 OC BRCA MUT after PARPi failure: 16 OC BRCA WT: pub 2023 |
| NCT02511795 | Ib | Adavosertib, Olaparib | A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours | Adavosertib+olaparib shows anti-tumor activity in ovarian cancer, particularly at the twice daily (BID) schedule ORR: 15% abs Apr 2019 and poster |